Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- ASKA Gets Asian Rights to Pieris’ Anemia Med
March 1, 2017
- Astellas, Affinivax Ink Global Partnership on Pneumococcal Vaccine
March 1, 2017
- Novo Files Once-Weekly GLP-1 in Japan
March 1, 2017
- Tolero Aims to File for AML Treatment Alvocidib in FY2018 in US: Sumitomo Dainippon
March 1, 2017
- Takeda to Transfer Part of CMC Functions to Bushu
March 1, 2017
- Kyowa Earns Rights for Astellas’ Extended-Release Quetiapine
February 28, 2017
- Shionogi to Comarket Methapain with Terumo
February 28, 2017
- Alecensa Gets Approval in Taiwan: Chugai
February 28, 2017
- Sanofi Files Atopic Dermatitis Treatment Dupilumab in Japan
February 28, 2017
- LEO Pharma Applies for Gel Formulation for Dovobet
February 28, 2017
- Daiichi Sankyo to Set Up Brand Strategy Unit to Spur Cancer Biz
February 27, 2017
- Eisai’s Yuji Matsue to Spearhead EA Pharma
February 27, 2017
- Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President
February 27, 2017
- Koichi Shimada to Lead Alfresa Pharma
February 24, 2017
- Takeda, Astellas to Build Joint Storage and Distribution System in Hokkaido
February 24, 2017
- JCR to Develop Pompe Disease Treatment Using Blood-Brain Barrier Technology
February 24, 2017
- Kyorin Holdings to Set Up Office in Indonesia
February 23, 2017
- Takeda Assigns High-Caliber Staffers for Govt’s Community-Based Care Initiative
February 22, 2017
- Generic Picks Will Depend on Regions as Joint Purchase Gets Underway, Iwasaki Says on Teva JV
February 22, 2017
- Debiopharm Takes Nippon Kayaku to Supreme Court over Elplat
February 22, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…